The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.
Johnson & Johnson's Spravato ... Advertisement The FDA approval of Spravato comes after a controlled study showed the nasal spray provided rapid improvement in the Montgomery-Asberg Depression ...
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults ... new major depression treatment to win FDA approval in more than three decades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results